Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention
Author(s): Dimitrios Alexopoulos , Charalampos Varlamos , Despoina-Rafailia Benetou Added: 3 years ago
Complex percutaneous coronary intervention (PCI) usually refers to procedures that include bifurcation with two stents implanted, the treatment of three or more lesions, the implantation of three or more stents, total stent length >60 mm, or a chronic total occlusion (CTO).1 However, as there is no universal definition, other features, such as left main (LM) or proximal left anterior… View more

Intervention
Author(s): Rik Rozemeijer , Wijnand P van Bezouwen , Michiel Voskuil , et al Added: 3 years ago
Dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitor is prescribed in the treatment of acute coronary syndrome (ACS) or following percutaneous coronary intervention (PCI) for drug-eluting stent (DES) implantation. An important misconception remains that DAPT should be prescribed to prevent stent thrombosis. Although this may seem obvious, it should be emphasized that the… View more

Intervention
Antiplatelet and Anticoagulation Therapy in ACS
Author(s): Colin T Phillips , Michael C Gavin Added: 3 years ago
Acute coronary syndrome (ACS) occurs most often when a vulnerable intracoronary plaque ruptures or erodes to expose a prothrombotic core, precipitating thrombus formation by way of platelet activation,1–3 The spectrum of ACS includes non-ST segment-elevation (NSTE) ACS, where a vulnerable plaque threatens downstream coronary perfusion manifest as an increase in symptom frequency and/or duration … View more

Prevention & Chronic Conditions

MI/ACS
Antithrombotic Therapy in Chronic Total Occlusion Interventions
Author(s): Iosif Xenogiannis , Charalampos Varlamos , Despoina-Rafailia Benetou , et al Added: 2 years ago

Intervention
Author(s): Peter J Fitzgerald , Martin B Leon Added: 3 years ago
An unintended consequence of the market success of drug-eluting stents has been a growing concern about their safety and safety-related costs. These devices have been so quickly and widely adopted that their market penetration already equals that of some of the most popular pharmaceutical drugs. Consequently, the absolute significance of even a low incidence of side effects becomes magnified by… View more

Intervention
TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention
Author(s): Johny Nicolas , Usman Baber , Roxana Mehran Added: 3 years ago
Seminal clinical trials conducted in the balloon angioplasty and bare metal stent era established the superiority of dual antiplatelet therapy (DAPT) as compared with aspirin monotherapy or anticoagulation with respect to the prevention of thrombotic events.1,2 Other studies found that the benefits of DAPT are durable for at least 1 year and extend to patients with acute coronary syndromes.3–5… View more

Anticoagulation
Antithrombotics in LM and Bifurcation PCI
Author(s): Charalampos Varlamos , Ioannis Lianos , Despoina-Rafailia Benetou , et al Added: 2 years ago

Intervention
Platelet Function Testing and Genotyping in Complex PCI
Author(s): Athanasios Moulias , Angeliki Papageorgiou , Dimitrios Alexopoulos Added: 2 years ago

Intervention
ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR
Author(s): Duk-Woo Park Added: 2 years ago
In this short interview, Dr Duk-Woo Park (Asan Medical Center, KR) discusses the findings from the ADAPT-TAVR Randomized Clinical Trial (NCT03284827). The trial investigated Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR. Presented first at ACC.22, ADAPT-TAVR shows that the overall incidence of leaflet thrombosis on CT scans was less… View more

Anticoagulation
Author(s): Donald E Cutlip Added: 3 years ago
Stent thrombosis has been recognized as a serious complication of coronary stent placement since the procedure was first reported in the 1980s.1 Subsequent aggressive peri-procedural anti-thrombotic strategies with inpatient transition to warfarin reduced the risk to about 3.5 % for subacute (30-day) stent thrombosis,2,3 a rate that would be unacceptable by current standards and did not account… View more

Prevention & Chronic Conditions

Intervention